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Abstract 
Background 
Antibody-mediated rejection is a major cause of premature graft loss in kidney transplantation. 
Multiple scoring systems are available to assess the HLA mismatch between donors and 
recipients at the molecular level, however, their correlation with the development of de novo 
donor-specific antibody (dnDSA) has not been compared in recipients on active 
immunosuppression.  
Methods 
HLA-DRβ1/3/4/5/DQα1β1 molecular mismatch was determined using eplet analysis, amino acid 
mismatch, and electrostatic mismatch for 596 renal transplant recipients and correlated with 
HLA-DR/DQ dnDSA development. The molecular mismatch scores were evaluated in 
multivariate models of posttransplant dnDSA free survival.  
Results  
Eplet mismatch correlated with amino acid mismatch and electrostatic mismatch (R
2
=0.85-0.96). 
HLA-DR dnDSA free survival correlated with HLA-DR eplet mismatch (HR 2.50 per 10 eplets 
mismatched, p<0.0001), amino acid mismatch (HR 1.49 per 10 amino acids mismatched, 
p<0.0001), and electrostatic mismatch (HR 1.23 per 10 units mismatched, p<0.0001). HLA-DQ 
dnDSA free survival correlated with HLA-DQ eplet mismatch (HR 1.98 per 10 eplets 
mismatched, p<0.0001), amino acid mismatch (HR 1.24 per 10 amino acids mismatched, 
p<0.0001), and electrostatic mismatch (HR 1.14 per 10 units mismatched, p<0.0001). All 3 
methods were significant multivariate correlates of dnDSA development after adjustment for 
recipient age, baseline immunosuppression, and nonadherence.  
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Conclusion 
HLA molecular mismatch represents a precise method of alloimmune risk assessment for renal 
transplant patients. This report highlights that the use of one method over the other is likely to be 
driven by familiarity and ease of use as highly correlated results are produced by each method. 
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Introduction 
Antibody-mediated rejection (ABMR) is a major cause of allograft dysfunction and allograft loss 
in kidney transplantation.(1-3) Improvements in HLA histocompatibility assessment and HLA 
antibody screening methods have made it possible to avoid transplanting across known donor-
specific antibodies (DSA), however, twenty to thirty percent of recipients develop de novo DSA 
(dnDSA) after 5-10 year of follow-up.(4) Therapy for late antibody mediated rejection is limited, 
therefore strategies to minimize dnDSA development through more precise HLA mismatch 
evaluation and through appropriate immunosuppression management are paramount.(5,6) 
 
Advances in genetics and protein modelling have made it possible to compare donor-recipient 
HLA mismatch at the molecular level. Traditional HLA mismatch quantification is constrained 
by a limited range of possible values (0, 1, or 2 per locus) at the whole antigen level. However, 
assessment of HLA mismatch at the molecular level enables quantification of the degree of 
mismatch and in turn immunogenicity between donor-recipient HLA improving the precision of 
immunological risk assessment with dnDSA development as the immune response readout. One 
such approach, based on enumerating all mismatched amino acid sequence polymorphisms on 
donor HLA and scoring them according to their physicochemical properties, has been shown to 
be independently associated with dnDSA development after graft failure.(7) An extension of this 
work, to assess the impact of donor sequence polymorphisms on the HLA tertiary structure, 
suggested that surface exposed antibody epitopes have unique electrostatic potential profiles that 
help explain HLA cross-reactive antigen groups.(8) A different approach, namely HLA 
Matchmaker, identifies small patches of surface exposed mismatched amino acids named 
“eplets” on each HLA molecule, which are hypothesized to drive DSA specificity.(9) The 
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quantity of mismatched eplets between donor and recipient alleles has been shown to correlate 
with dnDSA development, rejection, chronic glomerulopathy, and graft loss.(6,10,11,12) 
Whether one of these methods is  a superior correlate for dnDSA development in the setting of 
active immunosuppression has not been determined. 
 
The purpose of this analysis was to compare the eplet mismatch, amino acid mismatch, and 
electrostatic mismatch computational methodologies in a large cohort of well characterized renal 
transplant recipients for their correlation with the development of dnDSA posttransplant. Unique 
to this consecutive patient cohort is the strict exclusion of preexisting HLA DSA, the availability 
of high resolution donor and recipient HLA typing, immunosuppression adherence, serial sera 
obtained posttransplantation to characterize the timing of dnDSA onset, and long-term graft 
outcomes. 
 
Methods: 
Study Population 
Approval was obtained from the IRB (H2011: 211) and was in adherence with the 
declaration of Helsinki.  654 adult and pediatric consecutive renal transplants between 
January 1999 and January 2015 were considered for inclusion. Patients with primary 
nonfunction (n=16), or pretransplant DSA (n=42) were excluded, leaving 596 recipients 
(adult n=541, pediatric n=55) for analysis. Recipients who moved (n=21) or died with a 
functioning graft (n=82) were censored at last follow-up. Standard maintenance 
immunosuppression consisted of a calcineurin inhibitor (tacrolimus (86%) or cyclosporin 
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(14%)), mycophenolate mofetil, and prednisone.  Induction therapy with thymoglobulin 
(16%) or basiliximab (19%) was used in 35% of patients.  
HLA Typing and Molecular Mismatch Identification 
High-resolution (4-digit) Class II HLA typing (HLA-DRβ1/3/4/5 and HLA-DQα1/β1) was 
performed using sequence-specific oligonucleotide probes or sequence-specific primer 
technology (LABType HD SSO, Micro SSP, One Lambda). HLAMatchmaker software 
(HLA DRDQDP Matching version 2.0) was used to define Class II eplet mismatches 
(EpMM) between donors and recipients. The amino acid mismatch score (AAMS) and 
electrostatic mismatch score (EMS) for mismatched donor-recipient HLA combinations 
were determined using the Cambridge HLA Immunogenicity algorithm, as described 
previously.(7) For a given patient, when more than a single HLA mismatch was present 
within a locus, individual scores for each HLA mismatch were added to represent an 
overall immunogenicity score.   
Antibody Monitoring  
Posttransplant serum samples were collected and stored at 0,1, 2, 3, 6, 12, 18, and 24 
months, then yearly, or at the time of biopsy for graft dysfunction, as routine clinical 
practice in our program since 1990. Since 2007 posttransplant surveillance for dnDSA 
was instituted for all renal transplant patients.  DSA screening was performed using 
FlowPRA™ beads representing HLA-A, -B, -Cw, -DR, -DQ, and -DP antigens (One 
Lambda, Canoga Park, CA).  If the screening assay was positive, determination of HLA 
antibody specificities was performed using FlowPRA™ single antigen class I and II 
beads (One Lambda, Canoga Park, CA) and analyzed according to the manufacture’s 
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recommendations.  HLA antibody specificities were validated using LABScreen™ single 
antigen beads (One Lambda, Canoga Park, CA) using a threshold mean fluorescence 
intensity ≥ 500 (mean fluorescence intensity ≥1000 initially or on a subsequent sample in 
98% of cases). 
Pretransplant all patients had remote and immediate pretransplant sera screened by 
FlowPRA and if positive evaluated by FlowPRA single antigen beads. Even if the 
FlowPRA screen was negative, patient sera were still evaluated by FlowPRA single 
antigen beads if there was elevated risk of sensitization (eg pregnancy, history of 
transfusion). To rule out a DSA pretransplant the mismatched donor antigens had to be 
represented on the single antigen beads.  If donor specific antibodies were absent 
pretransplant, as determined by solid phase assays and a negative flow cross-match, and 
became detectable posttransplant they were classified as dnDSA. Patients with dnDSA 
had banked posttransplant serum tested to determine the approximate timing of dnDSA 
onset by FlowPRA single antigen beads. All patients continue to be prospectively tested 
for dnDSA according to the serum collection schedule outlined above to detect new 
dnDSA or to assess the persistence of existing dnDSA. 
Statistics 
Comparisons between baseline variables and clinical outcomes were done using Student’s t-test 
for parametric continuous variables and Wilcoxon-rank test for nonparametric data. Chi-squared 
or Fisher’s exact tests were used to test categorical variables. Comparisons across multiple 
groups were done using Kruskal–Wallis test for nonparametric data and ANOVA for parametric 
variables. Survival analysis was done by the Kaplan–Meier method using the log-rank test for 
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significance. Cox proportional hazards model was used to evaluate correlates of dnDSA free 
survival. Akaike information criterion (AIC) was calculated with Cox models to allow model 
comparisons within specific cohorts. The ability of the models to correctly classify subjects for 
their actual outcomes (dnDSA development) was examined using time-dependent receiver 
operator characteristic curves and area under the curve (AUC) statistics. Variables for 
multivariate regression were selected on the basis of bivariate screening, with p values ≤0.2 used 
to identify candidates for inclusion in the final model. The proportional hazard assumption was 
not violated (assessed by both Schoenfeld residuals and Harrell’s rho). Co-linearity was assessed 
and all variance inflation factors were less than 3. Statistical software used was R version 3.0.1 
and JMP (version 12.2). 
 
Results: 
This consecutive cohort (n=596) represented a low immunological risk group (96% first 
transplant, <10% with cPRA >80%) by conventional criteria. Median follow-up was 87 months 
(range 18-210). HLA-DR or DQ dnDSA developed in 66 recipients (11%) at a median of 55 
months (range of 6-170) posttransplant. At the time of dnDSA development 15/66 (23%) had 
HLA-DR dnDSA alone, 37/66 (56%) had HLA-DQ dnDSA alone, and 14/66 (21%) had both 
HLA-DR and DQ dnDSA. Significant correlates with Class II dnDSA were younger recipient 
and donor ages, Class II HLA-DR and DQ eplet mismatch, Class II HLA-DR and DQ amino 
acid mismatch, Class II HLA-DR and DQ electrostatic mismatch, greater cold ischemic time, 
CNI regimen (cyclosporine vs. tacrolimus), immunosuppression nonadherence, CNI coefficient 
of variation, and TCMR in the first year (Table 1). 
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Correlates of dnDSA Free Survival 
The median number of HLA-DRβ1/3/4/5 EpMM, AAMM, and EMS were 10 (range 0-41), 15 
(range 0-82), and 22 (range 0-147). HLA-DRβ1/3/4/5  EpMM (HR 2.50 per 10 mismatches, 95%CI 
1.71-3.64, p<0.0001), AAMM (HR 1.49, 95%CI 1.25-1.76, p<0.0001), and EMS (HR 1.23, 
95%CI 1.11-1.35, p<0.0001) were each significant univariate correlates of HLA-DR dnDSA free 
survival posttransplant (Table S1, SDC, http://links.lww.com/TP/B531).  
The median number of HLA-DQα1β1 EpMM, AAMM, and EMS was 13 (range 0-42), 18 
(range 0-97), 24 (range 0-164). HLA-DQ α1β1 EpMM (HR 1.98 per 10 mismatches, 
95%CI 1.53-2.58, p<0.0001), AAMM (HR 1.24, 95%CI 1.12-1.37, p<0.0001), and EMS 
(HR 1.14, 95%CI 1.07-1.21, p<0.0001) were each significant correlates of HLA-DQ 
dnDSA free survival posttransplant (Table S1, SDC, http://links.lww.com/TP/B531). 
Receiver operating characteristic curve analysis showed that all molecular mismatch 
methods had similar area under the curve scores (0.71 to 0.74) (Figure S1, SDC, 
http://links.lww.com/TP/B531).  
There were strong correlations between intra-locus molecular mismatch scores (Figure 
1). HLA-DRβ1/3/4/5 EpMM correlated with HLA-DRβ1 AAMM (R2=0.96), and EMS 
(R2=0.85). HLA-DQα1β1 EpMM correlated with HLA- DQα1β1 AAMM (R2=0.95), and 
EMS (R2=0.90). 
Multivariate Models 
In multivariate analyses, each of the molecular mismatch scores were independent correlates of 
dnDSA development after adjustment for younger recipient age, cyclosporine vs. tacrolimus, and 
nonadherence, (Table 2). Akaike information criterion (a measure of the relative quality of 
multivariate statistical models) were similar among the molecular mismatch scores examined. 
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Discussion 
Current assessment of donor-recipient histocompatibility and of the risk of humoral 
alloresponses after kidney transplantation is based on simple enumeration of HLA antigenic 
differences at individual class I and II loci without consideration of the relative immunogenicity 
of donor HLA mismatches according to the recipient HLA type. In the present study, we 
examined 3 different approaches for assessment of HLA class II immunogenicity ranging from 
simply enumerating the number of amino acid mismatches between donor and recipient HLA 
(AAMM), to counting the number of polymorphic surface accessible amino acid residues at 
discontinuous positions of donor HLA that cluster together to form a potential epitope (EpMM), 
to assessing the physicochemical disparity between the side chains of mismatched amino acids of 
donor and recipient HLA (EMS). Our study is the first to compare the capacity of these 
approaches to assess the risk of dnDSA development in a cohort of renal transplant patients on 
active immunosuppressive therapy and where the timing of dnDSA development posttransplant 
was monitored prospectively. The principal finding was that assessment of donor HLA 
immunogenicity based on AAMM, EpMM or EMS is superior to that of conventional HLA 
mismatch grade for assessing the risk of dnDSA development after kidney transplantation. We 
did not demonstrate an advantage in using one approach over another and, in this patient cohort, 
each method provided equivalent assessment of immunological risk associated with donor HLA 
class II mismatches.  
 
Development of dnDSA after kidney transplantation is associated with rejection, accelerated 
eGFR decline, and graft loss.(1,13) Currently no therapies have been proven effective to 
eliminate dnDSA after its development nor prevent progression of allograft dysfunction, 
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therefore, prevention of dnDSA is of paramount importance.(5) Nonadherence with 
immunosuppression, younger recipient age, cyclosporine based immunosuppression regimens, 
early T-cell mediated rejection and HLA mismatch have been established as independent 
correlates of dnDSA development.(6,10,14,15,16) Molecular assessment of HLA 
immunogenicity has gained the interest of the transplant community due to its ability to 
outperform traditional whole molecule mismatch as a correlate of dnDSA development, 
transplant glomerulopathy, and graft survival.(6,10,11) Humoral responses after kidney 
transplantation are frequently directed against donor HLA class II alloantigens and our study 
suggests that assessment of HLA-DR and -DQ immunogenicity based on mismatched eplets 
produces similar results compared to simply enumerating the number of amino acid 
polymorphisms between donor and recipient HLA molecules. This is not surprising given that 
AMS and EpMS both reflect differences in donor-recipient amino acid sequence and a strong 
correlation between the 2 scoring systems has been demonstrated in this and other studies.(7) 
EMS integrates information on the number of mismatched amino acids and the differences in 
electrostatic charge of their side chains and it is, therefore, correlated to the AAMM score. 
Previous studies suggested that consideration of the electrostatic charge of amino acid 
polymorphisms on donor HLA-A and -B alloantigens might provide useful information 
regarding their immunogenic potential,(7,17) but this and other studies do not support an 
advantage in using EMS, over EpMM and AAMM, for assessing the risk of DSA responses 
against HLA class II mismatches.(7,18) Larger studies and assessment of HLA electrostatic 
properties at the tertiary level are warranted to further explore the relationship between donor-
recipient HLA physicochemical differences and humoral alloresponses after transplantation. 
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HLAMatchmaker defines eplets by considering each polymorphic amino acid at or near the 
surface of the molecule and then asks the question what other polymorphic amino acids are 
nearby (3Å radius).(9)  This small patch of polymorphic amino acids is known as an eplet and its 
specific name is derived from the amino acids involved (ie 52PQ). By comparison, the amino 
acid mismatch software developed by Kosmoliaptsis et al aligns the amino acid sequence of 
donor and recipient HLA alleles and counts the number of mismatched amino acids irrespective 
of their position in three-dimensional space (as no advantage was previously demonstrated by 
exclusion of surface inaccessible polymorphisms).(17) The physicochemical approach compares 
the isoelectric points of mismatched amino acids between donor and recipient alleles and the 
differences are summed to represent an overall electrostatic mismatch score. The strong 
correlations between eplet mismatch, amino acid mismatch, and electrostatic mismatch (Figure 
1) are expected given that each scoring system examines a similar, but not identical, list of 
polymorphic amino acids (nonsurface exposed residues are excluded in HLAMatchmaker). 
 
Using the Akaike information criterion to compare EpMM, AAMM and EMS in 
multivariate models of dnDSA development (Table 2) revealed a small advantage to the 
HLAMatchmaker model. However, all 3 molecular mismatch methods had similar 
discrimination measures (AUC) and have been shown to outperform traditional HLA 
antigen matching in this and in previous reports, and a clinically meaningful difference of 
using one method over another to correlate with dnDSA development in clinical practice 
is doubtful. Due to the relatively small sample size and the associated risk of type II error, 
risk quantification should be interpreted with caution, and should be validated in a larger 
independent cohort. We acknowledge that this analysis focused on Class II dnDSA 
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because, in our cohort, dnDSA against donor HLA Class I mismatches alone was 
infrequent (2% of cohort) and only 1 patient in the entire cohort suffered allograft failure 
after developing isolated Class I dnDSA. HLA-DPα1β1 dnDSA development was tracked 
in this cohort (data not shown), however, was too infrequent for meaningful analysis. 
Development of mature humoral alloimmunity is dependent upon T cell help through 
linked recognition of HLA derived peptides presented in the context of recipient HLA 
class II molecules. Recent reports suggest that the presentation of allopeptides by HLA-
DR correlate with dnDSA development.(19) Although early in development, this may be 
a promising area for future research. Forthcoming studies, should also explore the 
immunogenicity of individual donor HLA, as determined by molecular mismatch 
methods, and the risk of de novo HLA-specific antibody development as a time-
dependent variable accounting for the effect of relevant confounders. 
 
In conclusion, HLA molecular mismatch methods enable precise assessment of alloimmune risk 
associated with renal transplantation. Donor HLA amino acid mismatch, electrostatic mismatch 
and eplet mismatch were each significant multivariate correlates of dnDSA development. 
Relevant studies in larger independent cohorts are warranted but, at present, the use of one 
method over the other is likely to be driven by familiarity and ease of use as highly correlated 
results are produced by each method. 
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Figure Legends: 
 
Figure 1. There was a strong correlation between eplet mismatch and amino acid mismatch (top 
row) and electrostatic mismatch (bottom row) scores at the HLA-DRβ1/3/4/5, HLA-DQ α1β1 loci. 
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Table 1. Recipient Characteristics 
 HLA-DR or 
DQ dnDSA 
(n=66) 
No HLA-DR 
or DQ 
dnDSA 
(n=530) 
p value 
First Transplant 97% 96% 0.9196 
Recipient Age at Transplant (years) 33.6±17.6 44.6±15.6 <0.0001 
Donor Age (years) 36.6±14.9 40.7±14.7 0.0438 
Living Donor 41% 50% 0.1712 
Recipient Ethnicity (Caucasian vs. other) 76% 65% 0.0718 
Cold Ischemic Time (hours) 8.7±5.7 6.8±5.4 0.0035 
Delayed Graft Function 14% 12% 0.6544 
Non-Adherence 41% 11% <0.0001 
Cyclosporin vs. Tacrolimus regime 39% 11% <0.0001 
Calcineurin inhibitor coefficient of variation 39.6±13.5 33.7±13.3 0.0083 
HLA-DRB1 Mismatch 1.4±0.5 1.2±0.7 0.1381 
HLA-DRB1/3/4/5 Mismatch 2.4±0.9 2.1±1.3 0.1838 
HLA-DQB1 Mismatch 1.2±0.5 1.1±0.7 0.2492 
HLA-DQA1/B1 Mismatch 2.3±0.9 2.2±1.4 0.5443 
HLA-DRB1/3/4/5 Eplet Mismatch 14.1±7.3 11.0±9.2 0.0014 
HLA-DQA1/B1 Eplet Mismatch 17.5±8.1 13.0±10.4 0.0002 
HLA-DRB1/3/4/5 Amino Acid Mismatch 23.2±14.9 18.4±17.5 0.0026 
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HLA-DQA1/B1 Amino Acid Mismatch 35.1±25.6 29.5±29.7 0.0136 
HLA-DRB1/3/4/5 Electrostatic Mismatch 30.7±17.8 23.2±22.7 0.0002 
HLA-DQA1/B1 Electrostatic Mismatch 47.7±29.6 35.2±37.4 <0.0001 
Episodes of TCMR ≥ Borderline in 0-12 months 1.4±1.4 0.6±1.1 <0.0001 
Episodes of TCMR ≥ 1A in 0-12 months 0.6±0.8 0.2±0.5 <0.0001 
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Table 2. Multivariate Correlates of dnDSA Development 
A. Eplet Mismatch DR dnDSA DQ dnDSA DR or DQ dnDSA 
  n=596, 29 events n=596, 51 events n=596, 66 events 
  HR p value HR p value HR p value 
Recipient Age at Transplant (years) 0.97 (0.95-0.99) 0.0192 0.97 (0.95-0.98) 0.0018 0.97 (0.96-0.99) 0.0006 
Nonadherence 3.07 (1.40-6.52) 0.0058 3.11 (1.71-5.58) 0.0002 3.09 (1.83-5.15) <0.0001 
Cyclosporin vs. Tacrolimus 2.14 (0.93-4.70) 0.0722 1.97 (1.06-3.52) 0.0251 2.28 (1.35-3.78) 0.0023 
HLA-DRB1/3/4/5 Eplet Mismatch 
(per 10 mismatches) 2.79 (1.84-4.27) <0.0001         
HLA-DQA1/B1 Eplet Mismatch (per 
10 mismatches)     2.00 (1.52-2.67) <0.0001     
HLA-DRB1/3/4/5 + HLA-DQA1/B1 
Eplet Mismatch (per 10 mismatches)         1.37 (1.18-1.58) <0.0001 
Akaike Information Criterion (AIC) 
for the Model   300.7   539.6   703.6 AC
CE
PT
ED
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B. Amino Acid Mismatch DR dnDSA DQ dnDSA DR or DQ dnDSA 
  n=596, 29 events n=596, 51 events n=596, 66 events 
  HR p value HR p value HR p value 
Recipient Age at Transplant (years) 0.97 (0.95-0.99) 0.0209 0.97 (0.95-0.98) 0.0015 0.97 (0.96-0.99) 0.0006 
Nonadherence 3.02 (1.38-6.46) 0.0067 3.37 (1.87-6.00) <0.0001 3.22 (1.91-5.43) <0.0001 
Cyclosporin vs. Tacrolimus 2.44 (1.05-5.48) 0.0382 2.03 (1.11-3.61) 0.0219 2.35 (1.40-3.88) 0.0017 
HLA-DRB1/3/4/5 Amino Acid 
Mismatch (per 10 mismatches) 1.57 (1.31-1.89) <0.0001         
HLA-DQA1/B1 Amino Acid 
Mismatch (per 10 mismatches)     1.24 (1.12-1.39) <0.0001     
HLA-DRB1/3/4/5 + HLA-DQA1/B1 
Amino Acid Mismatch (per 10 
mismatches)         1.12 (1.05-1.19) 0.0008 
Akaike Information Criterion (AIC) 
for the Model   302.9   549.4   710.2 AC
CE
PT
ED
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C. Electrostatic Mismatch DR dnDSA DQ dnDSA DR or DQ dnDSA 
  n=596, 29 events n=596, 51 events n=596, 66 events 
  HR p value HR p value HR p value 
Recipient Age at Transplant (years) 0.97 (0.95-0.99) 0.0309 0.97 (0.95-0.99) 0.0015 0.97 (0.96-0.99) 0.0006 
Nonadherence 2.94 (1.32-6.33) 0.0090 3.34 (1.86-5.95) <0.0001 3.30 (1.95-5.49) <0.0001 
Cyclosporin vs. Tacrolimus 2.47 (1.06-5.52) 0.0367 2.02 (1.11-3.61) 0.0230 2.37 (1.41-3.92) 0.0014 
HLA-DRB1/3/4/5 Electrostatic 
Mismatch (per 10 mismatches) 1.25 (1.13-1.38) <0.0001         
HLA-DQA1/B1 Electrostatic 
Mismatch (per 10 mismatches)     1.15 (1.07-1.22) <0.0001     
HLA-DRB1/3/4/5 + HLA-DQA1/B1 
Electrostatic Mismatch (per 10 
mismatches)         1.01 (1.00-1.01) 0.0016 
Akaike Information Criterion (AIC) 
for the Model   307.4   549.2   709.0 AC
CE
PT
ED
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